Key Takeaways
- • Sheridan Capital Partners has invested in Carolina Components Group (CCG), a healthcare and life sciences company founded in 2020, marking an entry into the medical device or component manufacturing sector.
- • The investment signals continued institutional appetite for healthcare-focused private equity deals despite broader market volatility in 2026.
- • CCG's founding date of 2020 positions the company as a relatively early-stage platform within Sheridan's portfolio, suggesting a growth-stage or lower-mid-market acquisition strategy.
- • The deal reflects ongoing consolidation trends in healthcare supply chain and component manufacturing, sectors that have attracted significant PE capital in recent years.
Summary
Sheridan Capital Partners has announced an investment in Carolina Components Group (CCG), a healthcare and life sciences company headquartered in the Carolinas and founded in 2020. While the primary source material contains limited detail on deal valuation, transaction structure, and strategic rationale, the announcement underscores Sheridan's continued focus on healthcare sector opportunities within its private equity portfolio.
CCG operates in the healthcare and life sciences space, a sector that has remained resilient for institutional capital deployment even as broader economic conditions shift. The company's founding in 2020 positions it as a platform business that has evolved through the pandemic recovery period, suggesting management has navigated a formative growth phase. Sheridan's investment likely aims to accelerate CCG's expansion through operational improvements, bolt-on acquisitions, or market development initiatives typical of lower-to-mid-market PE strategies.
The healthcare and life sciences private equity market continues to attract significant institutional capital flows. Component manufacturing and supply chain businesses within this vertical have proven attractive to PE investors seeking recurring revenue streams, essential market positioning, and consolidation opportunities. Sheridan's entry into the CCG investment reflects this broader trend of sponsors targeting companies that serve the expanding medical device, diagnostics, and healthcare infrastructure sectors.
The limited disclosure in this announcement is typical for mid-market PE transactions prior to full exit or material operational milestones. Institutional investors tracking Sheridan's portfolio construction will monitor CCG's subsequent performance metrics, management team additions, and potential bolt-on strategy announcements as leading indicators of the investment thesis's execution.
CCG operates in the healthcare and life sciences space, a sector that has remained resilient for institutional capital deployment even as broader economic conditions shift. The company's founding in 2020 positions it as a platform business that has evolved through the pandemic recovery period, suggesting management has navigated a formative growth phase. Sheridan's investment likely aims to accelerate CCG's expansion through operational improvements, bolt-on acquisitions, or market development initiatives typical of lower-to-mid-market PE strategies.
The healthcare and life sciences private equity market continues to attract significant institutional capital flows. Component manufacturing and supply chain businesses within this vertical have proven attractive to PE investors seeking recurring revenue streams, essential market positioning, and consolidation opportunities. Sheridan's entry into the CCG investment reflects this broader trend of sponsors targeting companies that serve the expanding medical device, diagnostics, and healthcare infrastructure sectors.
The limited disclosure in this announcement is typical for mid-market PE transactions prior to full exit or material operational milestones. Institutional investors tracking Sheridan's portfolio construction will monitor CCG's subsequent performance metrics, management team additions, and potential bolt-on strategy announcements as leading indicators of the investment thesis's execution.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.